Erratum: Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer (British Journal of Cancer (2014) 110 (133-145) DOI: 10.1038/bjc.2013.673);Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer

British Journal of Cancer

Volumn 110, Issue 1, 2014, Pages 133-145

  Kumar, J ^a   Fraser, F W ^a   Riley, C ^b   Ahmed, N ^b,c   McCulloch, D R ^a   Ward, A C ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cytokine; cytokine receptor; G CSF; G CSFR; JAK STAT; ovarian cancer; STAT3

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; JANUS KINASE 2; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTORS, COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84891877810     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.389     Document Type: Erratum

References (77)

1. Ahmed N, Riley C, Oliva K, Rice G, Quinn M (2005) Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer 92: 1475-1485. (Pubitemid 40705015)
2. Ahmed N, Riley C, Oliva K, Stutt E, Rice GE, Quinn MA (2003) Integrinlinked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J Pathol 201: 229-237. (Pubitemid 37258934)
3. Bohlius J, Reiser M, Schwarzer G, Engert A (2003) Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 122: 413-423. (Pubitemid 36951625)
4. Bookman MA (2012) First-line chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol 55: 96-113.
5. Brandstetter T, Ninci E, Bettendorf H, Perewusnyk G, Stolte J, Herchenbach D, Sellin D, Wagner E, Kochli OR, Bauknecht T (2001) Granulocyte colony-stimulating factor (G-CSF) receptor gene expression of ovarian carcinoma does not correlate with G-CSF caused cell proliferation. Cancer 91: 1372-1383. (Pubitemid 32267050)
6. Brandstetter T, Ninci E, Falken U, Wagner E, Hess R, Bauknecht T (1998) rhG-CSF affects genes involved in mitogen signalling and early gene expression in the ovarian cancer cell line HEY. Int J Cancer 75: 847-854. (Pubitemid 28134109)
7. Burleson KM, Boente MP, Pambuccian SE, Skubitz AP (2006) Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med 4: 6.
8. Chakraborty A, White SM, Lerner SP (2004) Granulocyte colony-stimulating factor receptor signals for b1-integrin expression and adhesion in bladder cancer. Urology 63: 177-183. (Pubitemid 38147589)
9. Christopher MJ, Link DC (2007) Regulation of neutrophil homeostasis. Curr Opin Hematol 14: 3-8. (Pubitemid 44885605)
10. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, Sessa C, Castiglione M (2010) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5): v23-v30.
11. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L, Ahmed N (2009) Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 100: 134-144.
12. Connor JP, Squatrito RC, Terrell KL, Antisdel BJ, Buller RE (1994) In vitro growth effects of colony-stimulating factors in ovarain cancer. Gynecol Oncol 52: 347-352. (Pubitemid 24125551)
13. Dunn SM, Coles LS, Lang RK, Gerondakis S, Vadas MA, Shannon MF (1994) Requirement for nuclear factor (NF)-kappa B p65 and NF-interleukin-6 binding elements in the tumor necrosis factor response region of the granulocyte colony-stimulating factor promoter. Blood 83: 2469-2479. (Pubitemid 24135838)
14. Eyles JL, Roberts AW, Metcalf D, Wicks IP (2006) Granulocyte colonystimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol 2: 500-510. (Pubitemid 44340426)
15. Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59: 221-226. (Pubitemid 8144854)
16. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF (2007) Mutations in the EGFR kinase domain mediates STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856. (Pubitemid 350224094)
17. Gits J, Van Leeuwen D, Carroll HP, Touw IP, Ward AC (2006) Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors. Leukemia 20: 2111-2118. (Pubitemid 44782836)
18. Goda K, Bacso Z, Szabo G (2009) Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets 9: 281-297.
19. Godoy-Tundidor S, Cavarretta IT, Fuchs D, Fiechtl M, Steiner H, Friedbichler K, Bartch G, Hobisch A, Culig Z (2005) Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Prostate 64: 209-216. (Pubitemid 40791771)
20. Gonzalez-Martin A, Toledo G, Chiva L (2010) Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting. Clin Transl Oncol 12: 418-430.
21. Grivennikov S, Karin M (2008) Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13: 7-9. (Pubitemid 350309747)
22. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM (2006) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res 66: 8026-8036. (Pubitemid 44299167)
23. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, Mceachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, Mccoon P, Cao ZA, Yu H, Jove R, Zinda M (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497.
24. Hirai K, Kumakiri M, Fujieda S, Sunaga H, Lao LM, Imamura Y, Ueda K, Fukuda M (2001) Expression of granulocyte colony-stimulating factor and its receptor in epithelial skin tumors. J Dermatol Sci 25: 179-188. (Pubitemid 32184505)
25. Hudson LG, Zeineldin R, Stack MS (2008) Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 25: 643-655.
26. Jones TR, Kang IH, Wheeler DB, Lindquist RA, Papallo A, Sabatini DM, Golland P, Carpenter AE (2008) CellProfiler Analyst: data exploration and analysis software for complex image-based screens. BMC Bioinformatics 9: 482.
27. Kamohara H, Ogawa M, Ishiko T, Sakamoto K, Baba H (2007) Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: involvement of regulation of LIF and its receptor expression. Int J Oncol 30: 977-983.
28. Kandala PK, Srivastava SK (2012) Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo. Drug Discov Ther 6: 94-101.
29. Karst AM, Drapkin R (2010) Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010: 932371.
30. Katayama N, Kita K, Kawakami K, Mitani H, Sugawara T, Mizuno S, Yonezawa A, Nishii K, Miwa H, Wada H, Minami N, Shiku H (1998) Granulocyte colony-stimulating factor and its receptor in acute promyelocytic leukemia. Am J Hematol 58: 31-35. (Pubitemid 28213556)
31. Kirschner K, Melton DW (2010) Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30: 3223-3232.
32. Lagunas VM, Melendez-Zajgla J (2008) Nuclear Factor-kappa B as a resistance factor to platinum-based antineoplasic drugs. Met Based Drugs 2008: 576104.
33. Lamprecht MR, Sabatini DM, Carpenter AE (2007) CellProfiler: free, versatile software for automated biological image analysis. Biotechniques 42: 71-75.
34. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK, Ahmed N (2011) Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 112: 2850-2864.
35. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N (2012) Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 7: e46858.
36. Lawrence T (2009) The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1: a001651.
37. Lee ES, Ko KK, Joe YA, Kang SG, Hong YK (2011) Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. Oncol Lett 2: 115-121.
38. Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177: 1053-1064.
39. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, Quinn MA, Rice GE (2007) Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer 120: 2426-2434. (Pubitemid 46642130)
40. Liongue C, Hall C, O'connell B, Crozier P, Ward AC (2009a) Zebrafish granulocyte colony-stimulating factor receptor signalling promotes myelopoiesis and myeloid cell migration. Blood 113: 2535-2546.
41. Liongue C, Wright C, Russell AP, Ward AC (2009b) Granulocyte colonystimulating factor receptor: stimulating granulopoiesis and much more. Int J Biochem Cell Biol 41: 2372-2375.
42. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCT method. Methods 25: 402-408. (Pubitemid 34164012)
43. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K, Murata Y (2004) Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 10: 7645-7654. (Pubitemid 39557528)
44. Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K, Chou AJ, Koshkina NV, Kleinerman ES (2007) Expression of granulocytecolony- stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocytecolony-stimulating factor administration. Cancer 110: 1568-1577. (Pubitemid 47463072)
45. Munstedt K, Hackethal A, Eskef K, Hrgovic I, Franke FE (2010) Prognostic relevance of granulocyte colony-stimulating factor in ovarian carcinomas. Arch Gynecol Obstet 282: 301-305.
46. Nakamae-Akahori M, Kato T, Masuda S, Sakamoto E, Kutsuna H, Hato F, Nishizawa Y, Hino M, Kitagawa S (2006) Enhanced neutrophil motility by granulocyte colony-stimulating factor: the role of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. Immunology 119: 393-403. (Pubitemid 44571058)
47. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, De Swart CA, Hirsch FR, Lund B, Van Houwelingen HC (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084-3092.
48. Ninci EB, Brandstetter T, Meinhold-Heerlein I, Bettendorf H, Sellin D, Bauknecht T (2000) G-CSF receptor expression in ovarian cancer. Int J Gynecol Cancer 10: 19-26. (Pubitemid 30219474)
49. Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, Puiffe ML, Arcand SL, Shen Z, Hebert J, Tonin PN, Provencher DM, Mes-Masson AM (2008) Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer 8: 152.
50. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29: 789-796.
51. Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN, Mes-Masson AM (2000) Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36: 357-361. (Pubitemid 30626747)
52. Punnonen R, Teisala K, Kuoppala T, Bennett B, Punnonen J (1998) Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors. Cancer 83: 788-796. (Pubitemid 28387706)
53. Ray-Coquard I, Paradiso D, Guastalla JP, Leduc B, Guichard F, Martin C, Chauvenet L, Haddad-Guichard Z, Lepille D, Orfeuvre H, Gautier H, Castera D, Pujade-Lauraine E (2007) Intensified dose of cyclophosphomidee with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer: a randomised study from the GINECO group. Br J Cancer 97: 1200-1205. (Pubitemid 350035814)
54. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11: 613-624. (Pubitemid 46730080)
55. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafe M (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117: 3988-4002. (Pubitemid 350224108)
56. Savarese TM, Mitchell K, Mcquain C, Campbell CL, Guardiani R, Wuu J, Ollari C, Reale F, Nelson BE, Chen A, Quesenberry PJ (2001) Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett 162: 105-115.
57. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS (2009) A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol 113: 210-215.
58. Shield K, Ackland ML, Ahmed N, Rice GE (2009) Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 113: 143-148.
59. Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N (2007) Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 6: 11.
60. Spinner DM, Brandstetter T, Kiechle-Schwarz M, Du Bois A, Angel P, Bauknecht T (1995) c-jun expression and growth stimulation in human ovarian carcinoma cell lines following exposure to cytokines. Int J Cancer 63: 423-427.
61. Touw IP, Van De Geijn GJ (2007) Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders. Front Biosci 12: 800-815. (Pubitemid 46846857)
62. Vasieva O (2011) The many faces of glutathione transferase pi. Curr Mol Med 11: 129-139.
63. Wang J, Shi YK, Wu LY, Wang JW, Yang S, Yang JL, Zhang HZ, Liu SM (2008) Prognostic factors for ovarian metastases from primary gastric cancer. Int J Gynecol 18: 825-832. (Pubitemid 352020167)
64. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, Li LZ (2010) Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295: 110-123.
65. Ward AC (2007) The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci 12: 608-618. (Pubitemid 46852810)
66. Ward AC, Hermans MHA, Smith L, Van Aesch YM, Schelen AM, Antonissen C, Touw IP (1999a) Tyrosine-dependent and independent mechanisms of STAT3 activation by the human granulocyte colony-stimulating factor (G-CSF) receptor are differentially utilized depending on G-CSF concentration. Blood 93: 113-124. (Pubitemid 29019395)
67. Ward AC, Smith L, De Koning JP, Van Aesch Y, Touw IP (1999b) Multiple signals mediate proliferation, differentiation and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells. J Biol Chem 274: 14956-14962.
68. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O (1990) Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 50: 6959-6965. (Pubitemid 20361098)
69. Wu KL, Miao H, Khan S (2007) JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signalingregulated, HIF-independent mechanism. Am J Physiol Renal Physiol 293: F1836-F1846. (Pubitemid 350179609)
70. Xu Z, Jiang Y, Steed H, Davidge S, Fu Y (2010) TGFbeta and EGF synergistically induce a more invasive phenotype of epithelial ovarian cancer cells. Biochem Biophys Res Commun 401: 376-381.
71. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M (2001) A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemialymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113: 375-382. (Pubitemid 32523141)
72. Yoon J, Cho SJ, Ko YS, Park J, Shin DH, Hwang IC, Han SY, Nam SY, Kim MA, Chang MS, Lee HS, Kim WH, Lee BL (2013) A synergistic interaction between transcription factors nuclear factor-kappaB and signal transducers and activators of transcription 3 promotes gastric cancer cell migration and invasion. BMC Gastroenterol 13: 29.
73. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6: 373-378. (Pubitemid 29260800)
74. Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Muller-Holzner E, Daxenbichler G, Offner FA, Dapunt O, Marth C (1998) Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 16: 1861-1868. (Pubitemid 28234733)
75. Zeineldin R, Muller CY, Stack MS, Hudson LG (2010) Targeting the EGF receptor for ovarian cancer therapy. J Oncol 2010: 414676.
76. Zhao Q, Wang C, Zhu J, Wang L, Dong S, Zhang G, Tian J (2011) RNAimediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study. J Exp Clin Cancer Res 30: 26.
77. Zhou J, Ong CN, Hur GM, Shen HM (2010) Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem Pharmacol 79: 1242-1250.